Literature DB >> 33674986

Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer.

Yamei Chen1, Ying Jin1,2, Xiao Hu1,3, Ming Chen4,5.   

Abstract

OBJECTIVE: Chemoradiotherapy (CRT) is the standard treatment for limited-stage small cell lung cancer (LS-SCLC), which can exert anti-tumor effects by regulating immune cells. Different immune cell subsets are associated with a specific sensitivity to CRT. The purpose of this study was to characterize the proportion or composition of peripheral lymphocytes in patients with LS-SCLC before and after CRT, and evaluate their prognostic value.
METHODS: A total of 98 patients with LS-SCLC were enrolled. The expression of CD3, CD4, CD8, CD45RA, CD45RO, CD38, CD56, and CD19 on the surface of peripheral blood cells was detected by flow cytometry and retrospectively analyzed. The relationship between the proportion of lymphocyte subsets, progression-free survival (PFS), and overall survival (OS) was evaluated using a log-rank test and Cox regression model.
RESULTS: The median PFS was 12.3 months and the median OS was 21.7 months. Compared with the pre-treatment specimens, post-treatment lymphocytes had increased proportions of CD3+, CD3+CD8+, CD8+CD38+ T cells, and NKT cells, and a decreased proportion of CD3+CD4+ T cells, CD4+CD45RA+ T cells, B cells, NK cells, and CD4/CD8 ratio. Univariate and multivariate analyses showed that prophylactic cranial irradiation, high percentages of CD4+CD45RA+, CD8+CD38+ T cells after CRT independently predicted superior PFS. Male patients with a high baseline CD4+CD45RO+ T cell ratio predicted a poor OS.
CONCLUSIONS: CRT induced changes in the proportion of circulating lymphocyte subsets in LS-SCLC, which is helpful for designing a regimen of immune drugs to be combined with CRT. The prognostic value of the proportion of lymphocytes aids in understanding the role of peripheral immune profiles in LS-SCLC.

Entities:  

Keywords:  Chemoradiotherapy; Lymphocyte subsets; Small cell lung cancer

Year:  2021        PMID: 33674986     DOI: 10.1007/s00262-021-02902-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  1 in total

1.  Aging of immune system: Immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults.

Authors:  Ling Qin; Xie Jing; Zhifeng Qiu; Wei Cao; Yang Jiao; Jean-Pierre Routy; Taisheng Li
Journal:  Aging (Albany NY)       Date:  2016-05       Impact factor: 5.682

  1 in total
  4 in total

1.  Pilot trial of topical MTS‑01 application to reduce dermatitis in patients receiving chemoradiotherapy for stage I‑III carcinoma of the anal canal.

Authors:  Deborah Citrin; Luca Valle; Kevin Camphausen; Theresa Cooley-Zgela; Deedee Smart; Michael Yao; James B Mitchell; William Thompson; Irini Sereti; Thomas Uldrick
Journal:  Int J Oncol       Date:  2022-04-19       Impact factor: 5.650

2.  A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer.

Authors:  Jie Peng; Dan Zou; Lijie Han; Zuomin Yin; Xiao Hu
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

3.  A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Authors:  Xiaoling Xu; Ding Wang; Wei Chen; Na Li; Rafal Suwinski; Antonio Rossi; Rafael Rosell; Jianxiang Zhong; Yun Fan
Journal:  Transl Lung Cancer Res       Date:  2021-12

4.  Changes of proportions of circulating lymphocyte subsets in cancer patients after chemotherapy.

Authors:  Weimin Wang; Yun Wang; Zong Cao
Journal:  Transl Cancer Res       Date:  2021-09       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.